IJMM International Journal of Molecular Medicine 1107-3756 1791-244X D.A. Spandidos 10.3892/ijmm.2024.5456 ijmm-55-01-05456 Review Interplay between lncRNAs and the PI3K/AKT signaling pathway in the progression of digestive system neoplasms (Review) ZhangXiaoyu1 ShiLei2 XingMengzhen2 LiChunjing1 MaFengjun1 MaYuning2 MaYuxia1 Department of Acupuncture and Massage College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250000, P.R. China Key Laboratory of New Material Research Institute, Institute of Pharmaceutical Research, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250000, P.R. China Correspondence to: Professor Yuning Ma, Key Laboratory of New Material Research Institute, Institute of Pharmaceutical Research, Shandong University of Traditional Chinese Medicine, 4655 University Road, Changqing, Jinan, Shandong 250000, P.R. China, E-mail: 60210001@sdutcm.edu.cn Professor Yuxia Ma, Department of Acupuncture and Massage College, Shandong University of Traditional Chinese Medicine, 4655 University Road, Changqing, Jinan, Shandong 250000, P.R. China, E-mail: myxia1976@163.com 01 2025 07 11 2024 55 1 15 03 09 2024 29 10 2024 Copyright: © 2024 Zhang et al. 2024 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Long non-coding RNA (lncRNA) is a class of non-coding RNA molecules located in the cytoplasm or nucleus, which can regulate chromosome structure and function by interacting with DNA, RNA, proteins and other molecules; binding to mRNA bases in a complementary manner, affecting the splicing, stabilization, translation and degradation of mRNA; acting as competing endogenous RNA competitively binds to microRNAs to regulate gene expression and participate in the regulation of various vital activities of the body. The PI3K/AKT signalling pathway plays a key role in numerous biological and cellular processes, such as cell proliferation, invasion, migration and angiogenesis. It has been found that the lncRNA/PI3K/AKT axis regulates the expression of cancer-related genes and thus tumour progression. The abnormal regulation of lncRNA expression in the lncRNA/PI3K/AKT axis is clearly associated with clinicopathological features and plays an important role in regulating biological functions. In the present review, the expression and biological functions of PI3K/AKT-related lncRNAs both in vitro and in vivo over recent years, were comprehensively summarized and analyzed. Their correlation with clinicopathological features was also evaluated, with the objective of furnishing a solid theoretical foundation for clinical diagnosis and the monitoring of efficacy in digestive system neoplasms. The present review aimed to provide a comprehensive overview of the expression and biological functions of PI3K/AKT-related lncRNAs in digestive system neoplasms and to assess their correlation with clinicopathological features. This endeavor seeks to establish a solid theoretical foundation for the clinical diagnosis and efficacy monitoring of digestive system tumors.

 long non-coding RNA PI3K AKT digestive system neoplasms biomarker NATCM's Project of High-level Construction of Key TCM Disciplines zyyzdxk-2023116 National Key Research and Development Program Funding Project 2022YFC3500403 Joint Fund of Natural Science Foundation of Shandong ZR2021LZY044 The present study was supported by the NATCM's Project of High-level Construction of Key TCM Disciplines (grant no. zyyzdxk-2023116), the National Key Research and Development Program Funding Project (grant no. 2022YFC3500403), the Joint Fund of Natural Science Foundation of Shandong (grant no. ZR2021LZY044) and the fifth batch of National Research and Training Program for Outstanding Clinical Talents of Traditional Chinese Medicine [grant no. National Letter of TCM Practitioners No. 1 (2022)]. Introduction

Cancer is one of the primary lethal factors in the world today. According to the latest data, the number of newly diagnosed cancers worldwide is projected to achieve 28.4 million (1). Furthermore, it has become an important public health concern that severely affects the lives of patients (2,3). Specifically, digestive system neoplasms represent a heterogeneous group of cancers characterized by diverse symptoms and complexities in diagnosis and treatment. Prognosis is often poor and influenced by various factors, highlighting the critical importance of early detection and comprehensive therapy for improving patient survival rate (4). In light of these challenges, there is an urgent need for increased efforts in the prevention and control of digestive system neoplasms (5). Long non-coding RNAs (lncRNAs) are non-coding RNA molecules >200 nucleotides in length, located in the nucleus or cytoplasm. In contrast to protein-coding genes, lncRNAs show a lower transcriptional level and poor sequence conservation, with less evolutionary pressure to bear. Compared with small RNA molecules, lncRNAs have a longer sequence, more complicated spatial structure, and are involved in more diverse and complex mechanisms. Additionally, lncRNAs modify target genes by binding to epigenetic-related proteins. They also inhibit the translation and degradation of target mRNA by binding to complementary bases. Additionally, lncRNAs participate in various regulatory activities in the body by serving as competing endogenous RNAs (ceRNAs). By competitively binding to mRNA with microRNAs (miRNAs or miRs), they regulate mRNA expression (6-8). Notably, previous findings have revealed that a large number of lncRNAs present aberrant expression during tumorigenesis and development, and some lncRNAs appear to have tumor-specific expression pattern. As a result, lncRNAs possess a multitude of biological functions in cancers, including epigenetic regulation, DNA damage and cell cycle regulation, miRNA regulation, participation in signal transduction pathway and cancer-inducing effect of hormones. This opens a new direction for tumor research (9-11).

The PI3K/AKT signaling pathway, composed of phosphoinositide 3-kinase (PI3K) family members and the downstream serine/threonine (Ser/Thr) protein kinases, is one of the most important intracellular signal transduction pathways. It plays a critical role in regulating cellular processes such as cell proliferation, survival, metabolism and angiogenesis (12,13). Activation of this pathway generally begins with the binding of growth factors to receptor tyrosine kinases (RTKs) on the cell surface, leading to the activation of PI3K, which in turn phosphorylates phosphatidylinositol (4,5)-bisphosphate (PIP2) to generate phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 then recruits AKT to the plasma membrane, where it is activated by phosphorylation. Once activated, AKT can modulate downstream targets involved in cell cycle progression (such as Cyclin D1), apoptosis inhibition (such as Bcl-2 and MDM2) and protein synthesis (via the mTOR pathway). lncRNAs are emerging as key regulators of the PI3K/AKT pathway. They can modulate this pathway through various mechanisms. Certain lncRNAs, such as MALAT1 and HOTAIR, can recruit chromatin-modifying complexes to specific genomic loci, resulting in the modification of gene expression that impacts the PI3K/AKT pathway. For example, MALAT1 has been reported to influence the expression of AKT1 by altering histone methylation at the AKT1 promoter. Certain lncRNAs can bind directly to proteins or mRNAs involved in the PI3K/AKT pathway. For example, lncRNA TINCR can physically interact with AKT1 and promote its activation, leading to enhanced PI3K/AKT signaling and cancer cell proliferation. Numerous lncRNAs function as molecular sponges by binding to miRNAs, which in turn regulate the expression of the PI3K/AKT pathway components. For instance, lncRNA UCA1 can sequester miR-143, a tumor-suppressive miRNA that inhibits AKT, thereby promoting PI3K/AKT activation and enhancing tumor growth and metastasis. Their ability to act as oncogenes or tumor suppressors through this pathway provides valuable insights into their potential as biomarkers or therapeutic targets in cancer treatment. For example, targeting the interaction between oncogenic lncRNAs and the PI3K/AKT pathway components may offer novel therapeutic strategies for improving outcomes of patients with cancer (14-16).

The novelty of the present review lies in its comprehensive exploration of the interplay between lncRNAs and the PI3K/AKT signaling pathway, specifically in digestive system neoplasms. While previous studies have examined individual aspects of lncRNA functions or the PI3K/AKT pathway (7,10), the current review integrates these elements to provide a more nuanced understanding of how lncRNAs regulate tumor progression through this critical pathway. Additionally, potential clinical implications, such as targeted therapeutic strategies and diagnostic applications, which have not been thoroughly addressed in prior research, were highlighted (14). The present review bridges basic molecular mechanisms with clinical relevance, offering new perspectives on treatment approaches for digestive system cancers.

 Mechanism of action of lncRNA

As transcriptome sequencing develops, increasing non-coding RNAs, including ~58% lncRNAs, have been discovered (17). It has been previously found that few lncRNAs contain small open reading frames that can be translated into bioactive polypeptides (18). For example, LINC00460 can encode small molecular polypeptides under certain conditions, whereas the molecular mechanism remains unknown (19). In spite of the incapability to encode proteins, most lncRNAs can still play a role in cellular biological processes through regulation of gene expression at the pre-transcriptional, transcriptional and post-transcriptional levels (20).

Pre-transcriptional regulation

During cancer development, lncRNAs can be observed in kinds of processes regulating epigenetic complex, such as the nucleosome positioning or histone modification in chromatin, by which lncRNAs inhibit or activate gene expression at the pre-transcriptional level. For instance, overexpression of MALAT1 promotes the recruitment of chromatin-modifying complexes to the promotor region of TSC2 gene, thereby suppressing the transcription of the TSC2 gene (21). Methylation is a common type of epigenetic modification. MIR20HG binds DNMT1 to promote the methylation of the CACNA2D2 promotor region and then suppress the gene expression of CACNA2D2 (22). DPP10-AS1 and protein-coding gene DPP10, which share 4 methylation sites, are upregulated synergistically in lung cancer, and DPP10-AS1 can regulate the methylation of DPP10 gene (23).

 Transcriptional regulation

Gene transcription is a process involving multiple factors including transcription factors, polymerases and enhancers. LncRNAs can bind with these factors and then regulate their activity, thereby affecting gene transcriptional control (24). For example, FOXC2-AS1 binding to transcription factor FOXC2 forms an RNA-RNA duplex, increasing FOXC2 expression and further enhancing ABCB1 gene expression (25). It was also reported that lncRNA could inhibit the transcription of specific mRNA by directly contacting RNA polymerase II during heat shock (26).

 Post-transcriptional regulation

LncRNAs can specifically bind with some other RNA or DNA in a base-pairing manner at any time point, and therefore, they play a role in mRNA transcription, processing, editing, translation or degradation (27). WT1-AS exhibits downregulated expression in non-small cell lung cancer (NSCLC), whereas lncRNA UCA1 shows upregulated expression in NSCLC, suggesting negative correlation between WT1-AS and UCA1. In addition, overexpression of WT1-AS inhibits the expression of UCA1 and promotes p53 to suppress the proliferation, migration and invasion of NSCLC cells, while by contrast, UCA1 expression potentiates the cellular biological behaviors (28). LncRNAs can also serve as ceRNAs to bind the 5′-end of miRNA and then affect the expression of downstream mRNA. For instance, lncRNA 5GAS5 regulates the expression of ATG3 through binding miR-23a (29). Additionally, miR-365 can target the 3′-non-coding region of ATG3 mRNA to suppress its expression, while the lncRNA PVT1 as a ceRNA for miR-365 can reduce the effect of miR-365 on ATG3 mRNA and thereby upregulate ATG3 mRNA expression (30).

 The PI3K/AKT signaling pathway in tumorigenesis

PI3K itself has the activity of Ser/Thr kinase and phosphatidylinositol kinase. It can be classified into three categories with varying structures and functions. Class I PI3Ks are the most extensively studied, and they are known as heterodimers containing one regulatory subunit and one catalytic subunit. The regulatory subunit, which is commonly known as p85 based on the first isotype, contains SH2 and SH3 domains that can bind with corresponding binding sites on target proteins. The catalytic subunit includes four isotypes: p110α, β, δ and γ, with the former two widely distributed in various cell types while the latter two only found in leukocytes. PI3K is composed of one regulatory subunit p85 and one catalytic subunit p110 (31). There are two pathways by which PI3K can be activated: One is the binding with the tyrosine kinase receptors at the cell surface through multiple extracellular factors (32); another one is the binding between Ras protein and p110 subunit (33).

AKT, also known as protein kinase B (PKB), is a 57-kDa Ser/Thr kinase and also a core protein of the PI3K/AKT/mTOR signaling. There are three isotypes: AKT1, AKT2 and AKT3 (34,35), with three common highly conserved domains: A pleckstrin homology (PH) domain in the N-terminus that mainly functions to promote AKT translocation to the plasma membrane, an ATP-binding kinase domain (KD) and a hydrophobic motif in the C-terminus that contain a binding site to activate kinase 3-phosphoinositide-dependent protein kinase 1 (PDK1) and enable allosteric modulation of PDK1 catalytic activity. There is also a linker region between the PH domain and the KD (36). Activated PI3K can phosphorylate PIP2 to form PIP3, which binds with the PH domain of AKT to induce AKT translocation to the cell membrane. The membrane localization of AKT makes AKT easy to be activated at Ser124 and Thr450 via phosphorylation induced by PDK, while the subsequent nuclear translocation enables AKT to regulate multiple downstream proteins (for example mTOR, Bad, caspase-9, NF-κB and forkhead box class O subfamily) and then play a regulatory role in cell survival, proliferation, apoptosis and angiogenesis (37-41).

The PI3K/AKT signaling pathway is regulated by multiple genes including tumor suppressor genes such as phosphatase and tensin (PTEN), Src Homology 2-containing Inositol phosphatase (SHIP) and carboxyl-terminal modulator protein (CTMP). PTEN can suppress the dephosphorylation of PIP3 back to PIP2, reducing the level of intracellular PIP3 and then inhibiting the activation of AKT and downstream molecules (42). CTMP can bind AKT to suppress its phosphorylation and then block downstream signal transduction. SHIP also can suppress the activation of AKT and downstream molecules via modulating the dephosphorylation of PIP3 (43). In addition, AKT can regulate its own activity through direct binding with some proteins, such as calcium-regulatory protein (Fig. 1).

Studies found that the PI3K/AKT signal transduction pathway is aberrantly activated in types of human malignancies, such as nervous system tumor (44,45), gynecological tumor (46-48) and gastrointestinal tumor (49-51). Additionally, it is closely correlated with tumorigenesis and development and plays an important role in proliferation (52), aerobic glycolysis (53), apoptosis (54), angiogenesis (55), invasion and metastasis (56), and chemoradiation resistance (57) of tumor cells.

 The lncRNA/PI3K/AKT axis in cancer

LncRNAs play an essential role in the occurrence and development of human cancer (58). However, study on lncRNAs alone is not sufficient to promote the diagnosis and treatment of cancer (10,59). Besides, use of conventional signaling pathways or molecules alone may also be useless. A substantial number of research has revealed the key roles of lncRNAs and the PI3K/AKT signaling pathway in various biological and cellular functions during cancer development, such as cell proliferation, invasion, migration and angiogenesis. Notably, the crosstalk between lncRNAs and the PI3K/AKT signaling pathway has sparked great interest in recent years. It has been reported that lncRNAs regulate cellular functions via interaction with the PI3K/AKT signaling pathway, thereby playing a role in control of cancer occurrence and development. With further in-depth studies on lncRNA structure and function, the role of the lncRNA/PI3K/AKT axis in cancer is expected to be further specified.

 Cell biological functions related to the lncRNA/PI3K/ AKT axis in digestive system neoplasms

The lncRNA/PI3K/AKT axis plays an important role in the occurrence and development of digestive system neoplasms by regulating the expression of cancer-related genes (Fig. 2). Current research may lay the foundation for further study on digestive system neoplasms progression and shed new light on lncRNA-based clinical applications (Table I). In this part, the expression and function of the PI3K/AKT-related lncRNAs in digestive system neoplasms are summarized.

Gastric cancer (GC)

GC is a malignancy originating from gastric mucosal epithelial cells. It has a high rate of incidence and case fatality but a low rate of early diagnosis, and patients usually experience poor outcomes (60-62). Studies have found that the PI3K/AKT-related lncRNAs, including HNF1A-AS1 (63), UCA1 (64), LINC01559 (65), FOXD1-AS1 (66), LINC01279 (67), LINC02465 (68), HOTAIR (69), LINC00511 (70), AK023391 (71), MALAT1 (72,73), TMPO-AS1 (74), CRNDE (75), ELFN1-AS1 (76) and HCG18 (77) exhibit significantly increased expression after GC occurs. The high expression of UCA1 (64), FOXD1-AS1 (66), HOTAIR (69) and MALAT1 (71) can promote cisplatin resistance in GC. LINC01559 (65) and LINC00511 (70) can regulate PTEN to trigger the PI3K/AKT pathway, thereby accelerating the progression of GC. Concerning the biological function, overexpression of LINC01279 (67), LINC02465 (68), MALAT1 (72,73), AK023391 (71) and CRNDE (75) can promote the proliferation, migration and invasion of GC via activating the PI3K/AKT signaling pathway. In addition, TMPO-AS1 (66) also plays a positive role in angiogenesis of GC cells. Animal experiments revealed that reductions in the expression of ELFN1-AS1 (76) and HCG18 (77) decreased the growth rate of xenograft GC tumor in mice.

In addition to the lncRNAs with increased expression in GC, lncRNAs including HOXD-AS2 (78), SLC25A5-AS1 (79), LOC101928316 (80), BX357664 (81), PICART1 (82), STXBP5-AS1 (83) and PCAT18 (84) show significantly decreased expression after GC occurs. The expression of HOXD-AS2 (78), SLC25A5-AS1 (79), LOC101928316 (80), BX357664 (81) and DLEU2 (85) in GC tissue is significantly lower than that in adjacent normal tissue, and notably, it has significant associations with tumor size, TNM stage and differentiation. Overexpression of LOC101928316 (80), PICART1 (82) and STXBP5-AS1 (83) can remarkably suppress the migration, invasion and proliferation of GC cells. Moreover, the result of xenograft experiment demonstrated significant suppression of tumor formation after PICART1 overexpression (82). PCAT18 was found to be highly correlated with tumor size and exhibit suppressive effect on GC tumor growth upon overexpression both in vivo and in vitro (84). While GC has been extensively studied for its interaction with lncRNAs in the context of the PI3K/AKT pathway, colorectal cancer (CRC) represents another major malignancy of the digestive system with significant findings in this area.

 CRC

CRC is one of the most common malignancies of the digestive system that leads to ~0.715 million deaths annually (1,86,87). The lncRNAs, including PlncRNA-1 (88), HCP5 (89), FOXCUT (90), AB073614 (91), TCONS_00012883 (92), TTN-AS1 (93), SNHG14 (94), KCNQ1OT1 (95), DLX6-AS1 (96), LBX2-AS1 (97) and LINC00115 (98), have significantly upregulated expression in CRC and promote the proliferation, invasion and migration of CRC cells by targeting the PI3K/AKT signaling pathway. TTN-AS1 is also correlated with the epithelial-mesenchymal transition (EMT) of CRC cells (93). An in vivo xenograft experiment revealed that suppression of PlncRNA-1 expression significantly inhibited the growth of tumor (88). Cellular experiment results demonstrated that HCP5 (89) and KCNQ1OT1 (95) induced cell cycle arrest in G0/G1 phase, while AB073614 (91) led to cell cycle arrest in G1 phase. SNHG7 (99) promotes the proliferation and metastasis of CRC, and it plays an oncogenic role by serving as a ceRNA for miR-34a to regulate GALNT7 expression and the PI3K/AKT/mTOR signaling pathway. LINC01296 (100) can facilitate the tumorigenesis, liver metastasis and chemoresistance of CRC cells in vivo.

Other lncRNAs, including LINC00657 (101), SNHG6 (102), ST3Gal6-AS1 (103), CASC7 (104) and RP11-462C24.1 (105), reversely exhibit significantly downregulated expression in CRC, and functionally, they repress the proliferation and metastasis but promote the apoptosis of CRC cells. LINC00657 suppresses the expression of CAPN7 through activating the PI3K/AKT pathway, and additionally, it exhibits significantly reduced expression upon distant metastasis (101). Overexpression of SNHG6 can decrease the activity and proliferation of colonocytes by targeting ETS1 and via the PI3K/AKT/mTOR axis (102). RP11-462C24.1 was reported to suppress the growth of xenograft CRC tumor in mice (105). Liver cancer, another prevalent and highly malignant tumor of the digestive system, also exhibits a strong association between lncRNAs and the PI3K/AKT pathway.

 Liver cancer

Liver cancer is one of the common malignancies with a poor prognosis. The 5-year survival rate in cases with advanced liver cancer was estimated ≤5%, posing a serious threat to the health and life of individuals (106,107). Some studies found that a large number of lncRNAs play a role in liver cancer via the PI3K/AKT signaling pathway. lncRNAs, including DUXAP10 (108), FGFR3-AS1 (109), LINC01133 (110), CASC11 (111), LINC02154 (112), NR027113 (113), RHPN1-AS1 (114), MIR205HG (115) and PTTG3P (116), promote the proliferation and invasion of liver cancer cells. Additionally, DUXAP10 (108), CASC11 (111), NR027113 (113) and PTTG3P (116) suppress the EMT of liver cancer cells. Downregulation of FGFR3-AS1 can significantly induce apoptosis in liver cancer cells and alleviate tumor growth in vivo. In addition, FGFR3-AS1 knock-out can lead to more significant cell cycle arrest in G0 phase in hepatocellular carcinoma (HCC) cells (109). CRNDE promotes the proliferation of HCC cells both in vivo and in vitro (117). LINC00473 may serve as a sponge for miR-29a-3p to upregulate Robo1 expression, activating the PI3K/AKT/mTOR signaling pathway and then promoting the proliferation, migration, invasion, progression and metastasis of liver cancer cells (118). LINC00963 activates the PI3K/AKT pathway to promote proliferation of HCC cells and prolong the G0/G1 phase (119). LINC01133 could induce cell cycle arrest in G1 phase, while suppression of LINC01133 was found to significantly suppress the xenograft tumor growth in vivo (113). LINC01419 can enhance the methylation of ZIC1 promotor to inhibit ZIC1 expression and activate the PI3K/AKT signaling pathway, thereby enhancing the malignant phenotypes of liver cancer cells in vitro while promoting the formation and metastasis of tumor in vivo (120). AC099850.3 demonstrates significant positive correlations with key immune checkpoint molecules: PD-1, PD-L1, PD-L2 and CTLA4, and therefore, it has the potential to be an immunotherapy target for HCC (121). HEIH acts as a sponge for miR-98-5p, and it activates the PI3K/AKT pathway via modulating the expression of miR-98-5p, thereby enhancing Sorafenib resistance in liver cancer (122). LINC02154 may promote the proliferation of HCC cells by enhancing the SPC24 promotor activity and activating the PI3K/AKT signaling pathway (112). MALAT1 may play a regulatory role in proliferation, apoptosis and autophagy of liver cancer cells via regulating the expression of miR-146a (123). MIR205HG promotes the progression of hepatoblastoma by acting as a sponge for miR-205-5p and activating the PI3K/AKT signaling pathway. NCK1-AS1 activates the PI3K/AKT signaling pathway through the miR-22-3p/YARS axis, in turn promoting HCC progression (124). ZEB1-AS1 significantly reduces the migration, invasion and metastasis of liver cancer cells both in vivo and in vitro. ZEB1-AS1 promotes HCC bone metastasis by targeting miR-302b and activating the PI3K/AKT signaling pathway (125). SNHG16 could exhibit increased expression in exosome from plasma of patients with HCC, while the exosome SNHG16 could promote angiogenesis via the miR-4500-GALNT1 axis (126).

The expression of FER1L4 (127), MEG3 (128) and TCL6 (129) in liver cancer tissue and cell lines is reduced, especially the expression of MEG3 in patients with advanced liver cancer. Overexpression of FER1L4 can significantly attenuate the proliferation, migration and invasion, and potentiate the apoptosis of liver cancer cells (127). Low expression of MEG3 can suppress AP1G1 expression and activate the PI3K/AKT signaling pathway, promoting the proliferation and invasion and accelerating cell cycle progress of liver cancer cells (128). TCL6 is a cancer-inhibiting molecule that can directly bind miR-106a-5p to regulate the PI3K/AKT signaling pathway, suppressing the proliferation, migration and invasion of HCC cells (129). Similar to liver cancer, pancreatic cancer (PC) involves similar molecular mechanisms, where lncRNAs regulate cancer progression via the PI3K/AKT signaling pathway.

 PC

PC is a digestive system tumor characterized by an occult onset and extremely high degree of malignancy (130,131). LINC01094 (132) and ABHD11-AS1 (133) show significantly increased expression in PC tissue, and SNHG1 (134) is highly expressed in pancreatic ductal adenocarcinoma tissue and predicts a poor prognosis. Downregulation of LINC01094, SNHG1 and ABHD11-AS1 can reduce the proliferation and metastasis of PC cells. In addition, decrease in ABHD11-AS1 can also inhibit the EMT of PC cells, and the reduction in SNHG1 can further promote cell apoptosis and alter cell cycle process. Moreover, the reductions in LINC01094 and SNHG1 could also suppress the formation and metastasis of xenograft PC tumor in mice. MEG3 acts as a cancer-inhibiting molecule in PC, and overexpression of MEG3 effectively decreases the proliferation, invasion and migration of PC cells (135). In addition to PC, esophageal squamous cell carcinoma (ESCC) is another aggressive malignancy where lncRNAs play critical roles, particularly through the PI3K/AKT signaling pathway.

 ESCC

ESCC is the most common among all histological types of esophageal cancer. It is more common in men than women, and the prognosis is often poor (136-138). The expression of lncRNA HCP5 is increased in ESCC. HCP5 stimulates the PI3K/AKT/mTOR signaling pathway through the miR-139-5p/PDE4A axis, which promotes the proliferation, migration, invasion but inhibits the apoptosis of ESCC cells, increasing the activity of ESCC cells (139). Another lncRNA, GAS5, also shows downregulated expression in ESCC, and overexpression of GAS5 suppresses the proliferation and migration of esophageal cancer cells by inhibiting the PI3K/AKT/mTOR signaling (140). Silence of LINC01014 can significantly increase the sensitivity of ESCC cells to Gefitinib and promote apoptosis in cells via the PI3K/AKT/mTOR signaling pathway (141). Lastly, gallbladder cancer (GBC), though less common than other gastrointestinal tumors, also involves dysregulated lncRNAs and PI3K/AKT signaling.

 GBC

GBC is the most common malignancy of the biliary system, and its incidence ranks sixth among all gastrointestinal tumors (142-144). SOX2-OT (145) and MALAT1 (146) exhibit significantly increased expression in cholangiocarcinoma (CCA) tissue, and they can promote the proliferation and metastasis of CCA cells. In addition, MALAT1 also facilitates the occurrence of EMT in CCA cells. CASC15 (147) displays high expression in intrahepatic CCA (ICC) and predicts a high TNM stage. Downregulation of CASC15 can reduce the proliferation, migration and invasion, increase the apoptosis, block the G1/S phase of ICC cells, and inhibit the development of xenograft tumor. LINC00152 shows significantly increased expression in GBC tissue and cells, and it can remarkably promote the proliferation and metastasis whereas suppress the apoptosis of GBC cells (148). Additionally, overexpression of LINC00152 can also potentiate the growth of tumor in vivo (Fig. 3).

 lncRNAs related to the PI3K/AKT pathway as biomarkers

Tumor markers are bioactive substances produced by the tumor tissue or through interactions between the host and the tumor. They can indicate the presence of a tumor and changes in its growth (149). They have significant implications for the tumor prevention, early diagnosis and differential diagnosis, classification, monitoring, treatment guiding, and prognosis which can compensate for the deficiency of other techniques in tumor diagnosis, treatment and prognosis (150). In recent years, an increasing number of studies have found that lncRNAs and the PI3K/AKT signaling pathway are potential biomarkers for the diagnosis, treatment and prognosis of types of digestive system neoplasms. In this section, the important roles of lncRNA and the PI3K/AKT signaling pathway in clinical practice are discussed (Table II).

Diagnostic biomarkers

The role of lncRNAs as diagnostic biomarkers has garnered significant attention, especially in their potential to provide non-invasive diagnostic approaches (10,151,152). Early screening is of great significance in cancer diagnosis and treatment (153,154). It was reported that abnormally expressed lncRNA is key for the cancer diagnosis, and it can be used as a non-invasive tumor biomarker to play an irreplaceable role in early tumor diagnosis. Multiple lncRNAs involved in the PI3K/AKT signaling pathway have been found with aberrant expression during the development of types of cancers. For instance, DLX6-AS1 (96), LINC00115 (98), LINC01296 (100) and CASC7 (104) exhibit significantly higher expression in the CRC tissue relative to that in normal tissue. lncRNAs, including LINC00963 (119), LINC02154 (112) and RHPN1-AS1 (114), also have remarkably increased expression in the liver cancer tissue. While in the PC, the expression of MEG3 (135), LINC01094 (132) and ABHD11-AS1 (133) also exhibit a significant increasing trend. Additionally, emerging evidence suggests that several of these lncRNAs may also play significant roles as biomarkers in other tumor types, such as breast and lung cancers, highlighting the potential for broader applications in cancer diagnostics and therapy.

 Prognosis prediction

In addition to aiding in diagnosis, lncRNAs also show considerable promise in predicting patient prognosis, providing insights into survival outcomes and treatment strategies. lncRNA has the potential to predict the prognosis of patients with cancer, providing an important guide for the cancer treatment. For example, TTN-AS1 (93), LINC02154 (112), LASTR (155), LINC00982 (156), DBH-AS1 (157) and LINC00265 (158) are significantly associated with the survival outcomes, such as overall survival (OS) and disease-free survival of patients with cancer. High expression of SNHG20 (159), MSC-AS1 (160), XLOC013218 (161) and LPP-AS2 (162) suggests a low OS in patients with glioblastoma. Additionally, lncRNA also has significant associations with other clinical features of cancer. In the GC, the expression of HNF1A-AS1 is closely related to the lymph node metastasis of the GC (63). While in the CRC, PlncRNA-1 and CASC7 show positive associations with lymph node metastasis and TNM stage in patients with CRC, while the expression of PlncRNA-1 is also related to the depth of tumor infiltration (88,104). Another lncRNA, LBX2-AS1, exhibits a clear correlation with the tumor size and early distant metastasis in patients with CRC (97). In liver cancer, the expression of LINC00963 is significantly correlated with the tumor size and TNM stage (119). In addition, the expression of RHPN1-AS1 in HCC shows a close relationship between vascular invasion, TNM stage and Barcelona Clinic Liver Cancer stage (114). The PTTG3P expression is also positively associated with the tumor size, TNM stage and poor survival in patients with HCC (116). In PC, high expression of ABHD11-AS1 and SNHG1 is associated with distant metastasis, TNM stage and tumor differentiation in a positive manner (126,133), whereas the expression of MEG3 is negatively associated with the tumor size, metastasis and vascular invasion (135). In GBC, high LINC00152 expression has a positive association with tumor progression, lymph node infiltration and TNM stage (148).

 Targeted therapies

Beyond diagnostic and prognostic capabilities, lncRNAs also provide new avenues for targeted therapies, which are revolutionizing cancer treatment by focusing on molecular pathways. Targeted therapy, which has been in clinical use since the late 1990s, has significantly enhanced the efficiency and specificity of cancer treatment. The approval of the first targeted drug, trastuzumab (Herceptin), for HER2-positive breast cancer in 1998 marked a pivotal moment in this therapeutic approach (163,164). lncRNA has significant implications for cancer progression via various signaling pathways. For instance, HNF1A-AS1 acts as a ceRNA to bind miR-30b-3p in the GC, activating the PI3K/AKT signaling pathway and then affecting the cancer progression (63). In the CRC, FOXCUT regulates cancer cell proliferation through increasing FOXC1 expression and activating the PI3K/AKT signaling pathway (90). While in liver cancer, MIR205HG as a molecular sponge for miR-205-5p activates the PI3K/AKT signaling pathway, thereby promoting the proliferation, migration and invasion of cancer cells (115). In addition, the GAS5 in OS serves as a ceRNA for miR-23a-3p to regulate the PI3K/AKT signaling pathway and increase PTEN expression, in turn suppressing the proliferation and invasion of tumor cells (165). ST3Gal6-AS1 is a target of the transcription factor FOXO1 and under the control of FOXO1. The positive feedback loop composed of ST3Gal6-AS1, ST3Gal6, PI3K/AKT and FOXO1 may play a key role in CRC progression (103).

 Conclusion

Digestive system tumors remain a significant health challenge globally, with increasing incidence rates and a pressing need for improved diagnostic and therapeutic strategies to enhance patient outcomes (166,167). lncRNAs are emerging biomarkers for cancer diagnosis and treatment, with complex lncRNA-centric regulatory networks playing a crucial role in cancer occurrence, development and treatment. Research has shown that lncRNAs can influence cancer through interactions with molecules involved in key signaling pathways, notably the PI3K/AKT signaling pathway, which significantly impacts tumorigenesis, progression, invasion and metastasis. However, agents targeting the PI3K/AKT signaling pathway currently used in clinical tumor suppression have limited efficacy, rendering combination regimens the preferred option for anti-cancer treatment. A substantial body of research indicates that lncRNAs both positively and negatively regulate biological functions during the occurrence and development of digestive system neoplasms via their interactions with the PI3K/AKT signaling pathway. However, differences in the expression patterns and functional roles of lncRNAs have been observed across various types of digestive system cancers. For instance, in GC, lncRNAs such as HOTAIR (69) and LINC00511 (70) are overexpressed, which enhances the PI3K/AKT signaling, contributing to tumor progression and poor prognosis. In GC, on the other hand, certain lncRNAs such as LINC01559 (65) have been implicated in PI3K/AKT pathway activation, driving proliferation and metastasis. In PC, it has been demonstrated that lncRNAs such as MEG3 (128) can modulate the PI3K/AKT pathway, influencing chemoresistance and cancer cell survival. These variations highlight the need for a more nuanced approach to targeting lncRNAs in different digestive system neoplasms. Furthermore, the expression of lncRNAs has been significantly associated with patient survival in these neoplasms, providing valuable prognostic information. However, the expression patterns and stability of lncRNAs in circulating body fluids (including urine and blood) require further exploration. Notably, lncRNAs have demonstrated potential in targeted therapies for other cancers, such as MALAT1 and HOTAIR, which are currently under investigation in breast (168,169), lung (170,171) and prostate cancers (172,173) for their roles in tumor progression and therapeutic responses. These findings suggest that lncRNA-targeted treatments could be expanded to gastrointestinal cancers, potentially opening new avenues for therapeutic intervention. To this end, a more thorough understanding of the functions and mechanisms of lncRNAs related to the PI3K/AKT signaling pathway in both physiological and pathophysiological conditions is essential. Moreover, the translational potential of these insights is currently limited by the lack of comprehensive clinical trial data. Structural and functional understanding of lncRNAs associated with the PI3K/AKT pathway remains sparse, obscuring the mechanisms of their interactions. Therefore, the development of targeted treatment strategies based on the PI3K/AKT pathway faces significant challenges due to the incomplete understanding of lncRNA structure and function. In conclusion, bridging the gap between basic research and clinical applications is imperative to unlock the therapeutic potential of targeting the lncRNA/PI3K/AKT axis in digestive system neoplasms. Future studies should focus on exploring clinical implications of these findings, investigating new diagnostic or therapeutic approaches, and considering strategies for targeting lncRNAs or modulating the PI3K/AKT pathway to improve patient outcomes. Additionally, comparative studies on lncRNA functions across different types of digestive system cancers could provide valuable insights into their diverse roles, further aiding in the development of more specific and effective therapeutic strategies. However, since lncRNAs are still in their emerging stages, there are currently no targeted drugs specifically for tumor treatment available in clinical settings. In the future, the authors shall focus on clinical applications and conduct in-depth research on the role of lncRNAs in tumors, aiming to aid clinicians.

 Availability of data and materials

Not applicable.

 Authors' contributions

XZ wrote the manuscript and created the images. LS and CL collected and organized the literature. MX and FM proofread the manuscript. YunM and YuxM are fully responsible for the study designing, research fields, drafting and finalizing the review. All authors contributed to the article. All authors read and approved the final version of the manuscript. Data authentication is not applicable.

 Ethics approval and consent to participate

Not applicable.

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 Acknowledgments

Not applicable.

 References SungHFerlayJSiegelRLLaversanneMSoerjomataramIJemalABrayFGlobal cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA Cancer J Clin71209249202110.3322/caac.2166033538338 GapsturSMDropeJMJacobsEJTerasLRMcCulloughMLDouglasCEPatelAVWenderRCBrawleyOWA blueprint for the primary prevention of cancer: Targeting established, modifiable risk factorsCA Cancer J Clin68446470201810.3322/caac.2149630303518 ArguetaEAMossSFThe prevention of gastric cancer by Helicobacter pylori eradicationCurr Opin Gastroenterol37625630202110.1097/MOG.000000000000077734411037 GaoSTanHLiDOridonin suppresses gastric cancer SGC-7901 cell proliferation by targeting the TNF-alpha/androgen receptor/TGF-beta signalling pathway axisJ Cell Mol Med2726612674202310.1111/jcmm.178413743188410494293 GaoSGangJYuMXinGTanHComputational analysis for identification of early diagnostic biomarkers and prognostic biomarkers of liver cancer based on GEO and TCGA databases and studies on pathways and biological functions affecting the survival time of liver cancerBMC Cancer21791202110.1186/s12885-021-08520-1342382538268589 ZhangXWangWZhuWDongJChengYYinZShenFMechanisms and functions of long non-coding RNAs at multiple regulatory levelsInt J Mol Sci205573201910.3390/ijms20225573317172666888083 BridgesMCDaulagalaACKourtidisALNCcation: lncRNA localization and functionJ Cell Biol220e202009045202110.1083/jcb.202009045334642997816648 FerrèFColantoniAHelmer-CitterichMRevealing protein-lncRNA interactionBrief Bioinform17106116201610.1093/bib/bbv031 PengWXKoiralaPMoYYLncRNA-mediated regulation of cell signaling in cancerOncogene3656615667201710.1038/onc.2017.184286047506450570 ChiYWangDWangJYuWYangJLong non-coding RNA in the pathogenesis of cancersCells81015201910.3390/cells8091015314805036770362 BachDHLeeSKLong noncoding RNAs in cancer cellsCancer Lett419152166201810.1016/j.canlet.2018.01.05329414303 LiLJChaiYGuoXJChuSLZhangLSEffects of endoplasmic reticulum stress on autophagy and apoptosis of human leukemia cells via inhibition of the PI3K/AKT/mTOR signaling pathwayMol Med Rep1778867892201829620275 PortaCPaglinoCMoscaATargeting PI3K/Akt/mTOR signaling in cancerFront Oncol464201410.3389/fonc.2014.00064247829813995050 HoxhajGManningBDThe PI3K-AKT network at the interface of oncogenic signalling and cancer metabolismNat Rev Cancer207488202010.1038/s41568-019-0216-77314312 FrumanDAChiuHHopkinsBDBagrodiaSCantleyLCAbrahamRTThe PI3K pathway in human diseaseCell170605635201710.1016/j.cell.2017.07.029288020375726441 XuFNaLLiYChenLRoles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumoursCell Biosci1054202010.1186/s13578-020-00416-0322660567110906 IyerMKNiknafsYSMalikRSinghalUSahuAHosonoYBarretteTRPrensnerJREvansJRZhaoSThe landscape of long noncoding RNAs in the human transcriptomeNat Genet47199208201510.1038/ng.3192255994034417758 NelsonBRMakarewichCAAndersonDMWindersBRTroupesCDWuFReeseALMcAnallyJRChenXKavalaliETA peptide encoded by a transcript annotated as long noncoding RNA enhances SERCA activity in muscleScience351271275201610.1126/science.aad4076268163784892890 NakanoYIsobeKKobayashiHKaburakiKIsshikiTSakamotoSTakaiYTochigiNMikamiTIyodaAClinical importance of long non-coding RNA LINC00460 expression in EGFR-mutant lung adenocarcinomaInt J Oncol562432572020 ZhouHFengBAbudoureyimuMLaiYLinXTianCHuangGChuXWangRThe functional role of long non-coding RNAs and their underlying mechanisms in drug resistance of non-small cell lung cancerLife Sci261118362202010.1016/j.lfs.2020.11836232871184 HuHWuJYuXZhouJYuHMaLLong non-coding RNA MALAT1 enhances the apoptosis of cardiomyocytes through autophagy inhibition by regulating TSC2-mTOR signalingBiol Res5258201910.1186/s40659-019-0265-0317839256883637 KangXKongFHuangKLiLLiZWangXZhangWWuXLncRNA MIR210HG promotes proliferation and invasion of non-small cell lung cancer by upregulating methylation of CACNA2D2 promoter via binding to DNMT1Onco Targets Ther1237793790201910.2147/OTT.S189468311908786529604 TianHPanJFangSZhouCTianHHeJShenWMengXJinXGongZLncRNA DPP10-AS1 promotes malignant processes through epigenetically activating its cognate gene DPP10 and predicts poor prognosis in lung cancer patientsCancer Biol Med18675692202110.20892/j.issn.2095-3941.2020.0136341065598330531 AliTGrotePBeyond the RNA-dependent function of LncRNA genesElife9e60583202010.7554/eLife.60583330951597584451 ZhangCLZhuKPMaXLAntisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2Cancer Lett3966675201710.1016/j.canlet.2017.03.01828323030 MarinerPDWaltersRDEspinozaCADrullingerLFWagnerSDKugelJFGoodrichJAHuman Alu RNA is a modular transacting repressor of mRNA transcription during heat shockMol Cell29499509200810.1016/j.molcel.2007.12.01318313387 RobinsonEKCovarrubiasSCarpenterSThe how and why of lncRNA function: An innate immune perspectiveBiochim Biophys Acta Gene Regul Mech1863194419202010.1016/j.bbagrm.2019.1944197185634 WanYYaoDFangFWangYWuGQianYLncRNA WT1-AS downregulates lncRNA UCA1 to suppress non-small cell lung cancer and predicts poor survivalBMC Cancer21104202110.1186/s12885-020-07767-4335143447844960 LiLHuangCHeYSangZLiuGDaiHKnockdown of long non-coding RNA GAS5 increases mir-23a by targeting ATG3 involved in autophagy and cell viabilityCell Physiol Biochem4817231734201810.1159/00049230030078013 YangLPengXJinHLiuJLong non-coding RNA PVT1 promotes autophagy as ceRNA to target ATG3 by sponging microRNA-365 in hepatocellular carcinomaGene69794102201910.1016/j.gene.2019.02.03630794914 AoRGuanLWangYWangJNSilencing of COL1A2, COL6A3, and THBS2 inhibits gastric cancer cell proliferation, migration, and invasion while promoting apoptosis through the PI3k-Akt signaling pathwayJ Cell Biochem11944204434201810.1002/jcb.26524 LiZDongHLiMWuYLiuYZhaoYChenXMaMHonokiol induces autophagy and apoptosis of osteosarcoma through PI3K/Akt/mTOR signaling pathwayMol Med Rep17271927232018 TamaskovicRSchwillMNagy-DavidescuGJostCSchaeferDCVerdurmenWPSchaeferJVHoneggerAPlückthunAIntermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS-p110 crosstalkNat Commun711672201610.1038/ncomms11672272559514895728 RevathideviSMunirajanAKAkt in cancer: Mediator and moreSemin Cancer Biol598091201910.1016/j.semcancer.2019.06.00231173856 ShariatiMMeric-BernstamFTargeting AKT for cancer therapyExpert Opin Investig Drugs28977988201910.1080/13543784.2019.1676726315943886901085 ShiwarskiDJDarrMTelmerCABruchezMPPuthenveeduMAPI3K class II α regulates δ-opioid receptor export from the trans-Golgi networkMol Biol Cell2822022219201710.1091/mbc.e17-01-0030285665545531736 LiuRChenYLiuGLiCSongYCaoZLiWHuJLuCLiuYPI3K/AKT pathway as a key link modulates the multidrug resistance of cancersCell Death Dis11797202010.1038/s41419-020-02998-6329731357515865 MayerIAArteagaCLThe PI3K/AKT pathway as a target for cancer treatmentAnnu Rev Med671128201610.1146/annurev-med-062913-051343 TianLZhaoZXieLZhuJMiR-361-5p suppresses chemoresistance of gastric cancer cells by targeting FOXM1 via the PI3K/Akt/mTOR pathwayOncotarget948864896201710.18632/oncotarget.23513 LaplanteMSabatiniDMmTOR signaling in growth control and diseaseCell149274293201210.1016/j.cell.2012.03.017225007973331679 LienECDibbleCCTokerAPI3K signaling in cancer: Beyond AKTCurr Opin Cell Biol456271201710.1016/j.ceb.2017.02.007283431265482768 MJRSVBMI1 and PTEN are key determinants of breast cancer therapy: A plausible therapeutic target in breast cancerGene678302311201810.1016/j.gene.2018.08.02230096458 BrownJSBanerjiUMaximising the potential of AKT inhibitors as anti-cancer treatmentsPharmacol Ther172101115201710.1016/j.pharmthera.2016.12.001 ChaiCSongLJHanSYLiXQLiMMicroRNA-21 promotes glioma cell proliferation and inhibits senescence and apoptosis by targeting SPRY1 via the PTEN/PI3K/AKT signaling pathwayCNS Neurosci Ther24369380201810.1111/cns.12785293163136489721 ZhangLLiuZDongYKongLE2F2 drives glioma progression via PI3K/AKT in a PFKFB4-dependent mannerLife Sci276119412202110.1016/j.lfs.2021.11941233774025 MiricescuDTotanAStanescu-SpinuIIBadoiuSCStefaniCGreabuMPI3K/AKT/mTOR signaling pathway in breast cancer: From molecular landscape to clinical aspectsInt J Mol Sci22173202010.3390/ijms22010173333753177796017 EdiriweeraMKTennekoonKHSamarakoonSRRole of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significanceSemin Cancer Biol59147160201910.1016/j.semcancer.2019.05.01231128298 ZhangWZhouQWeiYDaMZhangCZhongJLiuJShenJThe exosome-mediated PI3k/Akt/mTOR signaling pathway in cervical cancerInt J Clin Exp Pathol12247424842019 FattahiSAmjadi-MohebFTabaripourRAshrafiGHAkhavan-NiakiHPI3K/AKT/mTOR signaling in gastric cancer: Epigenetics and beyondLife Sci262118513202010.1016/j.lfs.2020.11851333011222 NarayanankuttyAPI3K/Akt/mTOR pathway as a therapeutic target for colorectal cancer: A review of preclinical and clinical evidenceCurr Drug Targets2012171226201910.2174/1389450120666190618123846 WangLLiSLuoHLuQYuSPCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K/AKT signaling in tumor cells and phenotypic polarization of macrophagesJ Exp Clin Cancer Res41303202210.1186/s13046-022-02477-0362420539563506 YangJQinGLuoMChenJZhangQLiLPanLQinSReciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMTCell Death Dis6e1829201510.1038/cddis.2015.197262038584650742 OhSKimHNamKShinISilencing of Glut1 induces chemoresistance via modulation of Akt/GSK-3β/β-catenin/survivin signaling pathway in breast cancer cellsArch Biochem Biophys636110122201710.1016/j.abb.2017.08.00928803837 KumarDHaldarSGorainMKumarSMulaniFAYadavASMieleLThulasiramHVKunduGCEpoxyazadiradione suppresses breast tumor growth through mitochondrial depolarization and caspase-dependent apoptosis by targeting PI3K/Akt pathwayBMC Cancer1852201810.1186/s12885-017-3876-2293106085759831 ChangCZWuSCChangCMLinCLKwanALArctigenin, a potent ingredient of arctium lappa L., induces endothelial nitric oxide synthase and attenuates subarachnoid hemorrhage-induced vasospasm through PI3K/Akt pathway in a rat modelBiomed Res Int2015490209201510.1155/2015/490209265395014619842 ChengTCDinZHSuJHWuYJLiuCISinulariolide suppresses cell migration and invasion by inhibiting matrix metal-loproteinase-2/-9 and urokinase through the PI3K/AKT/mTOR signaling pathway in human bladder cancer cellsMar Drugs15238201710.3390/md15080238 YuMQiBXiaoxiangWXuJLiuXBaicalein increases cisplatin sensitivity of A549 lung adenocarcinoma cells via PI3K/Akt/NF-κB pathwayBiomed Pharmacother90677685201710.1016/j.biopha.2017.04.00128415048 TanYTLinJFLiTLiJJXuRHJuHQLncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancerCancer Commun (Lond)41109120202110.1002/cac2.12108 WinkleMEl-DalySMFabbriMCalinGANoncoding RNA therapeutics-challenges and potential solutionsNat Rev Drug Discov20629651202110.1038/s41573-021-00219-z341454328212082 ChiaNYTanPMolecular classification of gastric cancerAnn Oncol27763769201610.1093/annonc/mdw04026861606 KarimiPIslamiFAnandasabapathySFreedmanNDKamangarFGastric cancer: Descriptive epidemiology, risk factors, screening, and preventionCancer Epidemiol Biomarkers Prev23700713201410.1158/1055-9965.EPI-13-1057246189984019373 SmythECNilssonMGrabschHIvan GriekenNCLordickFGastric cancerLancet396635648202010.1016/S0140-6736(20)31288-532861308 LiuHTMaRRLvBBZhangHShiDBGuoXYZhangGHGaoPLncRNA-HNF1A-AS1 functions as a competing endogenous RNA to activate PI3K/AKT signalling pathway by sponging miR-30b-3p in gastric cancerBr J Cancer12218251836202010.1038/s41416-020-0836-4323367547283217 DaiQZhangTPanJLiCLncRNA UCA1 promotes cisplatin resistance in gastric cancer via recruiting EZH2 and activating PI3K/AKT pathwayJ Cancer1138823892202010.7150/jca.43446323281927171500 WangLBoXYiXXiaoXZhengQMaLLiBExosome-transferred LINC01559 promotes the progression of gastric cancer via PI3K/AKT signaling pathwayCell Death Dis11723202010.1038/s41419-020-02810-5328953687477231 WuQMaJWeiJMengWWangYShiMFOXD1-AS1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K/AKT/mTOR pathwayMol Oncol15299316202110.1002/1878-0261.12728 ZhaoWZhaoXXuMChengZZhangZKnockdown of LINC01279 suppresses gastric cancer proliferation and migration by inhibiting PI3K/Akt/mTOR signaling pathwayJ Oncol20226228982202210.1155/2022/6228982363977619666029 HanLHaoYWangJWangZYangHWuXKnockdown of LINC02465 suppresses gastric cancer cell growth and metastasis Via PI3K/AKT pathwayHum Gene Ther Clin Dev301928201910.1089/humc.2018.17730632400 ChengCQinYZhiQWangJQinCKnockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34aInt J Biol Macromol10726202629201810.1016/j.ijbiomac.2017.10.154 WangQMaoXLuoFWangJLINC00511 promotes gastric cancer progression by regulating SOX4 and epigenetically repressing PTEN to activate PI3K/AKT pathwayJ Cell Mol Med2591129127202110.1111/jcmm.16656344279678500959 HuangYZhangJHouLWangGLiuHZhangRChenXZhuJLncRNA AK023391 promotes tumorigenesis and invasion of gastric cancer through activation of the PI3K/Akt signaling pathwayJ Exp Clin Cancer Res36194201710.1186/s13046-017-0666-2292821025745957 ZhuKRenQZhaoYlncRNA MALAT1 overexpression promotes proliferation, migration and invasion of gastric cancer by activating the PI3K/AKT pathwayOncol Lett17533553422019311867506507354 DaiQZhangTLiCLncRNA MALAT1 regulates the cell proliferation and cisplatin resistance in gastric cancer via PI3K/AKT pathwayCancer Manag Res1219291939202010.2147/CMAR.S243796322148507078812 HuYZhangYDingMXuRLong noncoding RNA TMPO-AS1/miR-126-5p/BRCC3 axis accelerates gastric cancer progression and angiogenesis via activating PI3K/Akt/mTOR pathwayJ Gastroenterol Hepatol3618771888202110.1111/jgh.15362 DuDXLianDBAminBHYanWLong non-coding RNA CRNDE is a novel tumor promoter by modulating PI3K/AKT signal pathways in human gastric cancerEur Rev Med Pharmacol Sci2153925398201729243780 ZhuangSHMengCCFuJJHuangJLong non-coding RNA ELFN1-AS1-mediated ZBTB16 inhibition augments the progression of gastric cancer by activating the PI3K/AKT axisKaohsiung J Med Sci38621632202210.1002/kjm2.1254835451560 MaFAnKLiYSilencing of long non-coding RNA-HCG18 inhibits the tumorigenesis of gastric cancer through blocking PI3K/Akt pathwayOnco Targets Ther1322252234202010.2147/OTT.S240965322560817092690 YaoLYePCTanWLuoYJXiangWPLiuZLFuZMLuFTangLHXiaoJWDecreased expression of the long non-coding RNA HOXD-AS2 promotes gastric cancer progression by targeting HOXD8 and activating PI3K/Akt signaling pathwayWorld J Gastrointest Oncol1212371254202010.4251/wjgo.v12.i11.1237332509587667460 LiXYanXWangFYangQLuoXKongJJuSDown-regulated lncRNA SLC25A5-AS1 facilitates cell growth and inhibits apoptosis via miR-19a-3p/PTEN/PI3K/AKT signalling pathway in gastric cancerJ Cell Mol Med2329202932201910.1111/jcmm.14200307934796433659 LiCLiangGYangSSuiJWuWXuSYeYShenBZhangXZhangYLncRNA-LOC101928316 contributes to gastric cancer progression through regulating PI3K-Akt-mTOR signaling pathwayCancer Med844284440201910.1002/cam4.2165312071556675725 LiangLCLiuLQLiuLLiuDLHeYRWanXZhuZQZhangBGLiuSJWuHHuLLong non-coding RNA BX357664 inhibits gastric cancer progression by sponging miR-183a-3p to regulate the PTEN expression and PI3K/AKT pathwayFood Chem Toxicol150112069202110.1016/j.fct.2021.11206933607219 LiJFLiWHXueLLZhangYLong non-coding RNA PICART1 inhibits cell proliferation by regulating the PI3K/AKT and MAPK/ERK signaling pathways in gastric cancerEur Rev Med Pharmacol Sci23588597201930720166 CenDHuangHYangLGuoKZhangJLong noncoding RNA STXBP5-AS1 inhibits cell proliferation, migration, and invasion through inhibiting the PI3K/AKT signaling pathway in gastric cancer cellsOnco Targets Ther1219291936201910.2147/OTT.S194463308810446415728 ChenPZhaoXWangHZhengMWangQChangWThe down-regulation of lncRNA PCAT18 promotes the progression of gastric cancer via MiR-107/PTEN/PI3K/AKT signaling pathwayOnco Targets Ther121101711031201910.2147/OTT.S225235318531876916702 HuJWangMYangYXingYLiSLncRNA DLEU2 silencing impedes the migration, invasion and EMT in gastric cancer cell by suppressing PI3K/AKT signaling pathwayImmunopharmacol Immunotoxicol44719731202210.1080/08923973.2022.207872735736813 WongMCSHuangJLokVWangJFungFDingHZhengZJDifferences in incidence and mortality trends of colorectal cancer worldwide based on sex, age, and anatomic locationClin Gastroenterol Hepatol19955966.e61202110.1016/j.cgh.2020.02.026 ZhangFSuTXiaoMRUNX3-regulated circRNA METTL3 inhibits colorectal cancer proliferation and metastasis via miR-107/PER3 axisCell Death Dis13550202210.1038/s41419-022-04750-8357107549203801 SongWMeiJZZhangMLong noncoding RNA PlncRNA-1 promotes colorectal cancer cell progression by regulating the PI3K/Akt signaling pathwayOncol Res26261268201810.3727/096504017X15031557924132 YunWKHuYMZhaoCBYuDYTangJBHCP5 promotes colon cancer development by activating AP1G1 via PI3K/AKT pathwayEur Rev Med Pharmacol Sci2327862793201931002129 ZhangXYiSXingGWuHZhuYGuoXZhangLFOXCUT promotes the proliferation and invasion by activating FOXC1/PI3K/AKT pathway in colorectal cancerCancer Manag Res1262696278202010.2147/CMAR.S259801328018727399466 WangYKuangHXueJLiaoLYinFZhouXLncRNA AB073614 regulates proliferation and metastasis of colorectal cancer cells via the PI3K/AKT signaling pathwayBiomed Pharmacother9312301237201710.1016/j.biopha.2017.07.02428738539 YangPLiJPengCTanYChenRPengWGuQZhouJWangLTangJTCONS_00012883 promotes proliferation and metastasis via DDX3/YY1/MMP1/PI3K-AKT axis in colorectal cancerClin Transl Med10e211202010.1002/ctm2.211331353467568852 CuiZHanBWangXLiZWangJLvYLong non-coding RNA TTN-AS1 promotes the proliferation and invasion of colorectal cancer cells by activating miR-497-mediated PI3K/Akt/mTOR signalingOnco Targets Ther121153111539201910.2147/OTT.S229104 PeiQLiuGSLiHPZhangYXuXCGaoHZhangWLiTLong noncoding RNA SNHG14 accelerates cell proliferation, migration, invasion and suppresses apoptosis in colorectal cancer cells by targeting miR-944/KRAS axis through PI3K/AKT pathwayEur Rev Med Pharmacol Sci2398719881201931799655 DuanQCaiLZhengKCuiCHuangRZhengZXieLWuCYuXYuJlncRNA KCNQ1OT1 knockdown inhibits colorectal cancer cell proliferation, migration and invasiveness via the PI3K/AKT pathwayOncol Lett20601610202010.3892/ol.2020.11619325659857286112 ZhangJJXuWRChenBWangYYYangNWangLJZhangYLThe up-regulated lncRNA DLX6-AS1 in colorectal cancer promotes cell proliferation, invasion and migration via modulating PI3K/AKT/mTOR pathwayEur Rev Med Pharmacol Sci2383218331201931646562 FangJYangJChenHSunWXiangLFengJLong non-coding RNA LBX2-AS1 predicts poor survival of colon cancer patients and promotes its progression via regulating miR-627-5p/RAC1/PI3K/AKT pathwayHum Cell3515211534202210.1007/s13577-022-00745-x35816228 FengWLiBWangJZhangHLiuYXuDChengKZhuangJLong non-coding RNA LINC00115 contributes to the progression of colorectal cancer by targeting miR-489-3p via the PI3K/AKT/mTOR pathwayFront Genet11567630202010.3389/fgene.2020.567630331936587525183 LiYZengCHuJPanYShanYLiuBJiaLLong non-coding RNA-SNHG7 acts as a target of miR-34a to increase GALNT7 level and regulate PI3K/Akt/mTOR pathway in colorectal cancer progressionJ Hematol Oncol1189201810.1186/s13045-018-0632-2299701226029165 LiuBPanSXiaoYLiuQXuJJiaLLINC01296/miR-26a/GALNT3 axis contributes to colorectal cancer progression by regulating O-glycosylated MUC1 via PI3K/AKT pathwayJ Exp Clin Cancer Res37316201810.1186/s13046-018-0994-x305478046295061 LeiYWangYHWangXFBaiJLINC00657 promotes the development of colon cancer by activating PI3K/AKT pathwayEur Rev Med Pharmacol Sci252460202133829423 MengSJianZYanXLiJZhangRLncRNA SNHG6 inhibits cell proliferation and metastasis by targeting ETS1 via the PI3K/AKT/mTOR pathway in colorectal cancerMol Med Rep20254125482019313222516691244 HuJShanYMaJPanYZhouHJiangLJiaLLncRNA ST3Gal6-AS1/ST3Gal6 axis mediates colorectal cancer progression by regulating α-2,3 sialylation via PI3K/Akt signalingInt J Cancer145450460201910.1002/ijc.3210330613961 HaoBWenHSunYLeZZhangZLiuMHuTLncRNA-CASC7 inhibits the proliferation and migration of colon cancer by negatively regulating the PI3K/Akt signaling pathwayJ Gastrointest Oncol1228032813202110.21037/jgo-21-643 ZhangHZhangGLiuHShanYZhangXRP11-462C24.1 suppresses proliferation and invasion of colorectal carcinoma cells by regulating HSP70 through PI3K/AKT signaling pathwayHum Cell34132151202110.1007/s13577-020-00426-7 MattiuzziCLippiGCurrent cancer epidemiologyJ Epidemiol Glob Health9217222201910.2991/jegh.k.191008.001318541627310786 ChengKCaiNZhuJYangXLiangHZhangWTumor-associated macrophages in liver cancer: From mechanisms to therapyCancer Commun (Lond)4211121140202210.1002/cac2.12345360693429648394 HanKLiCZhangXShangLDUXAP10 inhibition attenuates the proliferation and metastasis of hepatocellular carcinoma cells by regulation of the Wnt/β-catenin and PI3K/Akt signaling pathwaysBiosci Rep39BSR20181457201910.1042/BSR20181457 ZhuangJHeSWangGWangGNiJZhangSYeYXiaWLong noncoding RNA FGFR3-AS1 promotes hepatocellular carcinoma carcinogenesis via modulating the PI3K/AKT pathwayOncol Res2612571265201810.3727/096504018X15172756878992294633487844747 ZhengYFZhangXYBuYZLINC01133 aggravates the progression of hepatocellular carcinoma by activating the PI3K/AKT pathwayJ Cell Biochem12041724179201910.1002/jcb.27704 HanYChenMWangAFanXSTAT3-induced upregulation of lncRNA CASC11 promotes the cell migration, invasion and epithelial-mesenchymal transition in hepatocellular carcinoma by epigenetically silencing PTEN and activating PI3K/AKT signaling pathwayBiochem Biophys Res Commun508472479201910.1016/j.bbrc.2018.11.092 YueHWuKLiuKGouLHuangATangHLINC02154 promotes the proliferation and metastasis of hepatocellular carcinoma by enhancing SPC24 promoter activity and activating the PI3K-AKT signaling pathwayCell Oncol (Dordr)45447462202210.1007/s13402-022-00676-735543858 ChenZZhouZYHeCCZhangJLWangJXiaoZYDown-regulation of LncRNA NR027113 inhibits cell proliferation and metastasis via PTEN/PI3K/AKT signaling pathway in hepatocellular carcinomaEur Rev Med Pharmacol Sci2272227232201830468465 SongXZRenXNXuXJRuanXXWangYLYaoTTLncRNA RHPN1-AS1 promotes cell proliferation, migration and invasion through targeting miR-7-5p and activating PI3K/AKT/mTOR pathway in hepatocellular carcinomaTechnol Cancer Res Treat191533033820957023202010.1177/1533033820957023329107477491227 ZhangWLiangFLiQSunHLiFJiaoZLeiJLncRNA MIR205HG accelerates cell proliferation, migration and invasion in hepatoblastoma through the activation of MAPK signaling pathway and PI3K/AKT signaling pathwayBiol Direct172202210.1186/s13062-021-00309-3349965118740508 HuangJLCaoSWOuQSYangBZhengSHTangJChenJHuYWZhengLWangQThe long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinomaMol Cancer1793201810.1186/s12943-018-0841-x298032245970477 TangQZhengXZhangJLong non-coding RNA CRNDE promotes heptaocellular carcinoma cell proliferation by regulating PI3K/Akt/β-catenin signalingBiomed Pharmacother10311871193201810.1016/j.biopha.2018.04.12829864897 SongQZhangHHeJKongHTaoRHuangYYuHZhangZHuangZWeiLLong non-coding RNA LINC00473 acts as a microRNA-29a-3p sponge to promote hepatocellular carcinoma development by activating Robo1-dependent PI3K/AKT/mTOR signaling pathwayTher Adv Med Oncol121758835920937890202010.1177/1758835920937890329225207457704 WuJHTianXYAnQMGuanXYHaoCYLINC00963 promotes hepatocellular carcinoma progression by activating PI3K/AKT pathwayEur Rev Med Pharmacol Sci2216451652201829630107 HouYChenKLiaoRLiYYangHGongJLINC01419-mediated epigenetic silencing of ZIC1 promotes metastasis in hepatocellular carcinoma through the PI3K/Akt signaling pathwayLab Invest101570587202110.1038/s41374-021-00539-z33772101 ZhongFLiuSHuDChenLLncRNA AC099850.3 promotes hepatocellular carcinoma proliferation and invasion through PRR11/PI3K/AKT axis and is associated with patients prognosisJ Cancer1310481060202210.7150/jca.66092351544698824888 ShenQJiangSWuMZhangLSuXZhaoDLncRNA HEIH confers cell sorafenib resistance in hepatocellular carcinoma by regulating miR-98-5p/PI3K/AKT pathwayCancer Manag Res1265856595202010.2147/CMAR.S241383328211577419617 PengNHeJLiJHuangHHuangWLiaoYZhuSLong noncoding RNA MALAT1 inhibits the apoptosis and autophagy of hepatocellular carcinoma cell by targeting the microRNA-146a/PI3K/Akt/mTOR axisCancer Cell Int20165202010.1186/s12935-020-01231-w324351567222315 ZhouWWangJZhangJWangYJiangLGuoTLuoBXuQHuangYLncRNA NCK1-AS1 aggravates hepatocellular carcinoma by the miR-22-3p/YARS axis to activate PI3K/AKT signalingJ Gastrointestin Liver Dis314859202210.15403/jgld-407735306563 MaZJWangYLiHFLiuMHBiFRMaLMaHYanHLLncZEB1-AS1 regulates hepatocellular carcinoma bone metastasis via regulation of the miR-302b-EGFR-PI3K-AKT axisJ Cancer1151185128202010.7150/jca.45995327424597378930 LiSQiYHuangYGuoYHuangTJiaLExosome-derived SNHG16 sponging miR-4500 activates HUVEC angiogenesis by targeting GALNT1 via PI3K/Akt/mTOR pathway in hepatocellular carcinomaJ Physiol Biochem77667682202110.1007/s13105-021-00833-w34423392 WangXDongKJinQMaYYinSWangSUpregulation of lncRNA FER1L4 suppresses the proliferation and migration of the hepatocellular carcinoma via regulating PI3K/AKT signal pathwayJ Cell Biochem12067816788201910.1002/jcb.27980 SunLZhouJSunCMicroRNA-211-5p enhances analgesic effect of dexmedetomidine on inflammatory visceral pain in rats by suppressing ERK signalingJ Mol Neurosci681928201910.1007/s12031-019-01278-z30874971 LuoLHJinMWangLQXuGJLinZYYuDDYangSLRanRZWuGZhangTLong noncoding RNA TCL6 binds to miR-106a-5p to regulate hepatocellular carcinoma cells through PI3K/AKT signaling pathwayJ Cell Physiol23561546166202010.1002/jcp.2954432020591 WolpinBMPancreatic cancerHematol Oncol Clin North Am291314201510.1016/j.hoc.2015.06.002 ZhaoZLiuWPancreatic cancer: A review of risk factors, diagnosis, and treatmentTechnol Cancer Res Treat191533033820962117202010.1177/1533033820962117333570657768873 LuoCLinKHuCZhuXZhuJZhuZLINC01094 promotes pancreatic cancer progression by sponging miR-577 to regulate LIN28B expression and the PI3K/AKT pathwayMol Ther Nucleic Acids26523535202110.1016/j.omtn.2021.08.024346312828479296 QiaoXLvSXQiaoYLiQPYeBWangCCMiaoLLong noncoding RNA ABHD11-AS1 predicts the prognosis of pancreatic cancer patients and serves as a promoter by activating the PI3K-AKT pathwayEur Rev Med Pharmacol Sci2286308639201830575903 ZhangYZhangRLuoGAiKLong noncoding RNA SNHG1 promotes cell proliferation through PI3K/AKT signaling pathway in pancreatic ductal adenocarcinomaJ Cancer927132722201810.7150/jca.26207300877126072808 GuLZhangJShiMZhanQShenBPengClncRNA MEG3 had anti-cancer effects to suppress pancreatic cancer activityBiomed Pharmacother8912691276201710.1016/j.biopha.2017.02.04128320094 HaradaKRogersJEIwatsukiMYamashitaKBabaHAjaniJARecent advances in treating oesophageal cancerF1000Res9F1000 Faculty Rev-1189202010.12688/f1000research.22926.1330425187531047 LiYYangBMaYPengXWangZShengBWeiZCuiYLiuZPhosphoproteomics reveals therapeutic targets of esophageal squamous cell carcinomaSignal Transduct Target Ther6381202110.1038/s41392-021-00682-5347642418585941 ReichenbachZWMurrayMGSaxenaRFarkasDKarassikEGKlochkovaAPatelKTiceCHallTMGangJClinical and translational advances in esophageal squamous cell carcinomaAdv Cancer Res14495135201910.1016/bs.acr.2019.05.00431349905 XuJMaJGuanBLiJWangYHuSLncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signalingCell Cycle2013741388202110.1080/15384101.2021.1944512341900018344760 WangGSunJZhaoHLiHLong non-coding RNA (lncRNA) growth arrest specific 5 (GAS5) suppresses esophageal squamous cell carcinoma cell proliferation and migration by inactivating phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathwayMed Sci Monit2476897696201810.12659/MSM.910867303685176216480 FuXCuiGLiuSZhaoSLinc01014 regulates gefitinib resistance in oesophagus cancer via EGFR-PI3K-AKT-mTOR signalling pathwayJ Cell Mol Med2416701675202010.1111/jcmm.14860 BaiuIVisserBGallbladder cancerJAMA3201294201810.1001/jama.2018.1181530264121 HickmanLContrerasCGallbladder cancer: Diagnosis, surgical management, and adjuvant therapiesSurg Clin North Am99337355201910.1016/j.suc.2018.12.00830846038 RoaJCGarcíaPKapoorVKMaithelSKJavleMKoshiolJGallbladder cancerNat Rev Dis Primers869202210.1038/s41572-022-00398-y36302789 WeiCXWongHXuFLiuZRanLJiangRDIRF4-induced upregulation of lncRNA SOX2-OT promotes cell proliferation and metastasis in cholangiocarcinoma by regulating SOX2 and PI3K/AKT signalingEur Rev Med Pharmacol Sci2281698178201830556855 WangCMaoZPWangLWuGHZhangFHWangDYShiJLLong non-coding RNA MALAT1 promotes cholangiocarcinoma cell proliferation and invasion by activating PI3K/Akt pathwayNeoplasma64725731201710.4149/neo_2017_51028592124 ZhangYZhangLLuSXiangYZengCHeTDingYWangWLong non-coding RNA CASC15 promotes intrahepatic cholangiocarcinoma possibly through Inducing PRDX2/PI3K/AKT axisCancer Res Treat53184198202110.4143/crt.2020.1927812017 CaiQWangZQWangSHLiCZhuZGQuanZWZhangWJUpregulation of long non-coding RNA LINC00152 by SP1 contributes to gallbladder cancer cell growth and tumor metastasis via PI3K/AKT pathwayAm J Transl Res8406840812016278299935095302 CheungPKMaMHTseHFYeungKFTsangHFChuMKMKanCMChoWCSNgLBWChanLWCWongSCCThe applications of metabolomics in the molecular diagnostics of cancerExpert Rev Mol Diagn19785793201910.1080/14737159.2019.165653031414918 WuLQuXCancer biomarker detection: Recent achievements and challengesChem Soc Rev4429632997201510.1039/C4CS00370E25739971 GoyalBYadavSRMAwastheeNGuptaSKunnumakkaraABGuptaSCDiagnostic, prognostic, and therapeutic significance of long non-coding RNA MALAT1 in cancerBiochim Biophys Acta Rev Cancer1875188502202110.1016/j.bbcan.2021.18850233428963 NemethKBayraktarRFerracinMCalinGANon-coding RNAs in disease: From mechanisms to therapeuticsNat Rev Genet25211232202410.1038/s41576-023-00662-1 RebbeckTRBurns-WhiteKChanATEmmonsKFreedmanMHunterDJKraftPLadenFMucciLParmigianiGPrecision prevention and early detection of cancer: Fundamental principlesCancer Discov8803811201810.1158/2159-8290.CD-17-141529907587 BorrebaeckCAKPrecision diagnostics: Moving towards protein biomarker signatures of clinical utility in cancerNat Rev Cancer17199204201710.1038/nrc.2016.15328154374 XiaMZhuWTaoCLuYGaoFLncRNA LASTR promote lung cancer progression through the miR-137/TGFA/PI3K/ AKT axis through integration analysisJ Cancer1310861096202210.7150/jca.660678899365 XuDYuJZhuangSZhangSHongZYuanCOverexpression of long non-coding RNA LINC00982 suppresses cell proliferation and tumor growth of papillary thyroid carcinoma through PI3K-ATK signaling pathwayBiosci Rep39BSR20191210201910.1042/BSR20191210312629686629942 LiuZBWangJALvRQDownregulation of long non-coding RNA DBH-AS1 inhibits osteosarcoma progression by PI3K-AKT signaling pathways and indicates good prognosisEur Rev Med Pharmacol Sci2314181427201930840262 MaLKuaiWXSunXZLuXCYuanYFLong noncoding RNA LINC00265 predicts the prognosis of acute myeloid leukemia patients and functions as a promoter by activating PI3K-AKT pathwayEur Rev Med Pharmacol Sci2278677876201830536332 GaoXFHeHQZhuXBXieSLCaoYLncRNA SNHG20 promotes tumorigenesis and cancer stemness in glioblastoma via activating PI3K/Akt/mTOR signaling pathwayNeoplasma66532542201910.4149/neo_2018_180829N65630943748 LiCFengSChenLMSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathwayMol Cell Biochem476699713202110.1007/s11010-020-03937-x7873112 ZhouJXuNLiuBWangCHeZLenahanCTangWZengHGuoHlncRNA XLOC013218 promotes cell proliferation and TMZ resistance by targeting the PIK3R2-mediated PI3K/AKT pathway in gliomaCancer Sci11326812692202210.1111/cas.15387356376009357648 ZhangXNiuWMuMHuSNiuCLong non-coding RNA LPP-AS2 promotes glioma tumorigenesis via miR-7-5p/EGFR/PI3K/AKT/c-MYC feedback loopJ Exp Clin Cancer Res39196202010.1186/s13046-020-01695-8329627427510091 SwainSMShastryMHamiltonETargeting HER2-positive breast cancer: Advances and future directionsNat Rev Drug Discov22101126202310.1038/s41573-022-00579-0 HurvitzSAHeggRChungWPImSAJacotWGanjuVChiuJWYXuBHamiltonEMadhusudanSTrastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trialLancet401105117202310.1016/S0140-6736(22)02420-5 LiuJChenMMaLDangXDuGLncRNA GAS5 suppresses the proliferation and invasion of osteosarcoma cells via the miR-23a-3p/PTEN/PI3K/AKT pathwayCell Transplant29963689720953093202010.1177/0963689720953093331212687784500 GaoSTanHGangJInhibition of hepatocellular carcinoma cell proliferation through regulation of the Cell Cycle, AGE-RAGE, and Leptin signaling pathways by a compound formulation comprised of andrographolide, wogonin, and oroxylin A derived from Andrographis Paniculata(Burm.f.) NeesJ Ethnopharmacol329118001202410.1016/j.jep.2024.118001 GourdKESMO gastrointestinal cancers congress 2024Lancet Oncol25961202410.1016/S1470-2045(24)00383-838972325 KimJPiaoHLKimBJYaoFHanZWangYXiaoZSiverlyANLawhonSETonBNLong noncoding RNA MALAT1 suppresses breast cancer metastasisNat Genet5017051715201810.1038/s41588-018-0252-3303491156265076 CantileMDi BonitoMCerroneMCollinaFDe LaurentiisMBottiGLong non-coding RNA HOTAIR in breast cancer therapyCancers (Basel)121197202010.3390/cancers12051197323973827281113 BhatAAAfzalOAfzalMGuptaGThapaRAliHHassan AlmalkiWKazmiIAlzareaSISaleemSMALAT1: A key regulator in lung cancer pathogenesis and therapeutic targetingPathol Res Pract253154991202410.1016/j.prp.2023.154991 LoewenGJayawickramarajahJZhuoYShanBFunctions of lncRNA HOTAIR in lung cancerJ Hematol Oncol790201410.1186/s13045-014-0090-4254911334266198 NanniSAielloASalisCReACencioniCBacciLPiercontiFPintoFRipoliCOstanoPMetabolic reprogramming by Malat1 depletion in prostate cancerCancers (Basel)1315202010.3390/cancers13010015333751307801945 LiTLiuNGaoYQuanZHaoYYuCLiLYuanMNiuLLuoCWuXLong noncoding RNA HOTAIR regulates the invasion and metastasis of prostate cancer by targeting hepaCAMBr J Cancer124247258202110.1038/s41416-020-01091-17782544

A schematic representation of the PI3K/Akt pathway. The figure was created using Adobe Illustrator 2024 (v28.0; Adobe Inc.). RTK, receptor tyrosine kinase; GPCR, G protein-coupled receptor; PIP2, phosphatidylinositol 4,5-biphosphate; PIP3, phosphatidylinositol (3,4,5)-triphosphate; PDK1, phosphoinositide-dependent kinase-1.

lncRNAs associated with PI3K/AKT in digestive system neoplasms. The figure was created using Adobe Illustrator 2024 (v28.0; Adobe Inc.). LINC, long intergenic non-coding; lncRNA, long non-coding RNA.

Specific mechanisms of digestive system tumor progression between long non-coding RNAs and the PI3K/AKT pathway. The figure was created using Adobe Illustrator 2024 (v28.0; Adobe Inc.). miR, microRNA; LINC, long intergenic non-coding.

Role and biological functions of lncRNA/PI3K/AKT axis in progression of digestive system neoplasms.

Category, digestive system neoplasms
A, Gastric cancer
First author, year lncRNA Role Function Related targets (Refs.)
Yao et al, 2020 HOXD-AS2 Tumor suppressor Invasion, migration, proliferation, and apoptosis HOXD8, PI3K, AKT (78)
Li et al, 2019 SLC25A5-AS1 Tumor suppressor Tumour size, TNM stage and lymph node metastasis, cell proliferation, apoptosis miR-19a-3p, PTEN, PI3K, AKT (79)
Liu et al, 2020 HNF1A-AS1 Oncogene Invasion, metastasis, angiogenesis and lymphangiogenesis miR-30b-3p, PI3K, AKT (63)
Li et al, 2019 LOC101928316 Tumor suppressor Migration, invasion and proliferation PI3K, AKT, mTOR (80)
Wang et al, 2020 LINC01559 Oncogene Proliferation, migration miR-1343-3p, PGK1, PTEN, PI3K, AKT (65)
Wu et al, 2021 FOXD1-AS1 Oncogene Proliferation, metastasis PIK3CA, PI3K, AKT, mTOR (66)
Zhao et al, 2022 LINC01279 Oncogene Tumor size, TNM stage, and metastasis, invasion, proliferation, cell cycle PI3K, AKT, mTOR (67)
Han et al, 2019 LINC02465 Oncogene Proliferation, migration, invasion and EMT PI3K, AKT (68)
Cheng et al, 2018 HOTAIR Oncogene Cisplatin-resistance miR-34a, PI3K, AKT (69)
Wang et al, 2021 LINC00511 Oncogene Proliferation, migration, stemness, apoptosis and EMT process SOX4, PTEN, PI3K, AKT (70)
Huang et al, 2017 AK023391 Oncogene Invasion, apoptosis and cell cycle PI3K, AKT (71)
Hu et al, 2022 DLEU2 Tumor suppressor Cell apoptosis, migration, invasion and EMT process PI3K, AKT (85)
Zhu et al, 2019 MALAT1 Oncogene Proliferation, migration and invasion PI3K, AKT (72)
Dai et al, 2020 MALAT1 Oncogene Proliferation, migration, invasion PI3K, AKT, STAT3 (73)
Wu et al, 2021 TMPO-AS1 Oncogene Proliferation, migration and angiogenesis. miR-126-5p, BRCC3, PI3K, AKT, mTOR (66)
Dai et al, 2020 UCA1 Oncogene Proliferation, Cisplatin-resistance EZH2, PI3K, AKT (64)
Liang et al, 2021 BX357664 Tumor suppressor Proliferation, migration, apoptosis and invasion miR-183-3p, PTEN, PI3K, AKT (81)
Du et al, 2017 CRNDE Oncogene Proliferation, migration and invasion PI3K, AKT (75)
Zhuang et al, 2022 ELFN1-AS1 Oncogene Proliferation, invasion, migration and apoptosis ZBTB16, PI3K, AKT (76)
Li et al, 2019 PICART1 Tumor suppressor Proliferation, apoptosis PI3K, AKT, ERK, MAPK (82)
Cen et al, 2019 STXBP5-AS1 Tumor suppressor Proliferation, migration, and invasion PI3K, AKT (83)
Ma et al, 2020 HCG18 Oncogene Proliferation, migration, invasion, and apoptosis PI3K, AKT (77)
Chen et al, 2019 PCAT18 Tumor suppressor Proliferation miR-107, PTEN, PI3K, AKT (84)
B, Colorectal cancer
Song et al, 2018 PlncRNA-1 Oncogene Proliferation, migration, invasion and apoptosis PI3K, AKT (88)
Yun et al, 2019 HCP5 Oncogene Proliferation, migration and cell cycle AP1G1, PI3K, AKT (89)
Zhang et al, 2020 FOXCUT Oncogene Proliferation and invasion FOXC1, PI3K, AKT (90)
Wang et al, 2017 AB073614 Oncogene Proliferation, migration, invasion, apoptosis and cell cycle PI3K, AKT (91)
Yang et al, 2020 TCONS_ 00012883 Oncogene Proliferation and metastasis DDX3, YY1, MMP1, PI3K, AKT (92)
Cui et al, 2019 TTN-AS1 Oncogene Proliferation, migration, invasion and EMT mir-497, PI3K, AKT (93)
Pei et al, 2019 SNHG14 Oncogene Proliferation, migration, invasion and apoptosis miR-944/KRAS, PI3K, AKT (94)
Duan et al, 2020 KCNQ1OT1 Oncogene Proliferation, migration and invasion PI3K, AKT (95)
Zhang et al, 2019 DLX6-AS1 Oncogene Proliferation, invasion and migration PI3K, AKT, mTOR (96)
Fang et al, 2022 LBX2-AS1 Oncogene Proliferation, metastasis and apoptosis miR-627-5p, RAC1, PI3K, AKT (97)
Feng et al, 2020 LINC00115 Oncogene Proliferation, apoptosis, migration and invasion miR-489-3p, PI3K, AKT (98)
Li et al, 2018 SNHG7 Oncogene Proliferation, metastasis, cell cycle, and apoptosis miR-34a, GALNT7, PI3K, AKT, mTOR (99)
Liu et al, 2018 linc01296 Oncogene Tumorigenesis, liver metastasis and chemoresistance MUC1, PI3K, AKT (100)
Lei et al, 2021 LINC00657 Tumor suppressor Proliferation, invasion, and apoptosis CAPN7, PI3K, AKT (101)
Meng et al, 2019 SNHG6 Tumor suppressor Proliferation, invasion and migration ETS1, PI3K, AKT, mTOR (102)
Hu et al, 2019 ST3Gal6-AS1 Tumor suppressor Proliferation, metastasis, and apoptosis PI3K, AKT (103)
Hao et al, 2021 CASC7 Tumor suppressor Proliferation, invasion and migration PI3K, AKT (104)
Zhang et al, 2021 RP11-462C24.1 Tumor suppressor Proliferation, cell cycle, apoptosis and invasion HSP70, PI3K, AKT (105)
C, Liver cancer
Tang et al, 2018 CRNDE Oncogene Proliferation PI3K, AKT, GSK3β-Wnt, β-catenin (117)
Han et al, 2019 DUXAP10 Oncogene Migration, EMT, apoptosis, proliferation and invasion PI3K, AKT (108)
Zhuang et al, 2018 FGFR3-AS1 Oncogene Proliferation, cell apoptosis, G0 stage, migration and invasion PI3K, AKT (109)
Song et al, 2020 LINC00473 Oncogene Proliferation, migration, invasion and metastasis miR-29-3p, Robo1, PI3K, AKT, mTOR (118)
Wu et al, 2018 LINC00963 Oncogene Proliferation, G0/G1 phase PI3K, AKT (119)
Chen et al, 2018 LINC01133 Oncogene Proliferation, cell apoptosis, G1 phase, migration and invasion PI3K, AKT (113)
Hou et al, 2021 LINC01419 Oncogene Proliferation and apoptosis ZIC1, PI3K, AKT (120)
Zhong et al, 2022 AC099850.3 Oncogene Proliferation, metastatic and apoptosis PRR11, PI3K, AKT (121)
Han et al, 2019 CASC11 Oncogene Migration, invasion and EMT PI3K, AKT (111)
Shen et al, 2020 HEIH Oncogene Invasion, apoptosis and migration miR-98-5p, PI3K, AKT (122)
Peng et al, 2020 Linc02154 Oncogene Proliferation, migration and invasion SPC24, PI3K, AKT (123)
Chen et al, 2018 NR027113 Oncogene Proliferation, invasion, EMT and metastasis PTEN, PI3K, AKT (113)
Song et al, 2020 RHPN1-AS1 Oncogene Proliferation, migration and invasion miR-7-5p, PI3K, AKT, mTOR (114)
Peng et al, 2020 MALAT1 Oncogene Proliferation, apoptosis and autophagy miR-146a, PI3K, AKT (123)
Zhang et al, 2022 MIR205HG Oncogene Proliferative, migratory and invasion PI3K, AKT (115)
Zhou et al, 2022 NCK1-AS1 Oncogene Invasion, apoptosis and migration miR-22-3p, YARS, PI3K, AKT (124)
Ma et al, 2020 ZEB1-AS1 Oncogene Migration, invasion, metastasis PI3K, AKT (125)
Huang et al, 2018 PTTG3P Oncogene Proliferation, migration, EMT, invasion, metastasis, cell cycle and apoptosis PTTG1, PI3K, AKT (116)
Li et al, 2021 SNHG16 Oncogene Proliferation, migration and angiogenesis miR-4500, GALNT1, PI3K, AKT, mTOR (126)
Wang et al, 2019 FER1L4 Tumor suppressor Proliferation, migration, cell apoptosis and invasion PI3K, AKT (127)
Sun et al, 2019 MEG3 Tumor suppressor Proliferation, invasion and cell cycle AP1G1, PI3K, AKT (128)
Luo et al, 2020 TCL6 Tumor suppressor Proliferation, migration and invasion miR-106a-5p, PI3K, AKT (129)
D, Pancreatic cancer
Gu et al, 2017 MEG3 Oncogene Proliferation, invasion and apoptosis PI3K, AKT, Bcl-2, Bax, Cyclin D1, P53, MMP-2, MMP-9 (135)
Luo et al, 2021 LINC01094 Oncogene Proliferation and metastasis miR-577, LIN28B, PI3K, AKT (132)
Qiao et al, 2018 ABHD11-AS1 Oncogene Proliferation, migration, invasion, and EMT PI3K, AKT (133)
Zhang et al, 2018 SNHG1 Tumor suppressor Proliferation, apoptosis and cell cycle PI3K, AKT (134)
E, Esophageal squamous cell carcinoma
Fu et al, 2020 Linc01014 Oncogene Proliferation, apoptosis and gefitinib resistance EGFR, PI3K, AKT, mTOR (141)
Xu et al, 2021 HCP5 Oncogene Proliferation, apoptosis, migration and invasion PI3K, AKT, mTOR (139)
Wang et al, 2018 GAS5 Tumor suppressor Proliferation and migration PI3K, AKT, mTOR (140)
F, Gallbladder cancer
Wei et al, 2018 SOX2-OT Oncogene Proliferation and metastasis PI3K, AKT (145)
Wang et al, 2017 MALAT1 Oncogene Proliferation, EMT and metastasis PI3K, AKT (146)
Zhang et al, 2021 CASC15 Tumor suppressor Proliferation, migration, invasion, cell apoptosis and G1/S stage PRDX2, PI3K, AKT (147)
Cai et al, 2016 LINC00152 Oncogene Proliferation, metastasis and cell apoptosis SP1, PI3K, AKT (148)

LINC, long intergenic non-coding; EMT, epithelial-mesenchymal transition; lncRNA, long non-coding RNA; miR, microRNA.

Relationship between lncRNA/PI3K/AKT axis and clinical features in digestive system neoplasms.

First author, year Cancer type LncRNA Expression Related feature (Refs.)
Ma et al, 2020 Gastric cancer HCG18 Upregulated Stage of tumor node metastasis and invasion depth (77)
Du et al, 2017 CRNDE Upregulated Invasion depth, TNM stage and lymph node metastasis (75)
Hu et al, 2021 TMPO-AS1 Upregulated Clinical prognosis (74)
Han et al, 2019 LINC02465 Upregulated Tumour size, tumour stage, lymph node metastasis and differentiation (68)
Zhao et al, 2022 LINC01279 Upregulated Tumor size, TNM stage, and metastasis of lymph nodes (67)
Yao et al, 2020 HOXD-AS2 Downregulated Lymph node metastasis (78)
Hu et al, 2022 DLEU2 Downregulated Tumor differentiation, cancer antigen 19-9 (CA19-9) and Lauren histologic classification (85)
Chen et al, 2019 PCAT18 Downregulated Tumor size (84)
Li et al, 2019 SLC25A5-AS1 Downregulated Tumour size, TNM stage and lymph node metastasis (79)
Dai et al, 2020 UCA1 Downregulated TNM stage (64)
Li et al, 2019 LOC101928316 Downregulated TNM stage and degree of differentiation (80)
Song et al, 2018 Colorectal cancer PlncRNA-1 Upregulated Depth of invasion, lymph node metastasis, TNM stage and overall survival (88)
Yun et al, 2019 HCP5 Upregulated Survival period (89)
Wang et al, 2017 AB073614 Upregulated Tumor grade, tumor size, cell differentiation status, and the presence of distant metastases (91)
Cui et al, 2019 TTN-AS1 Upregulated Overall survival (93)
Zhang et al, 2019 DLX6-AS1 Upregulated Advanced T stage and distant metastasis (96)
Fang et al, 2022 LBX2-AS1 Upregulated Tumor volume and early distant metastasis (97)
Feng et al, 2020 LINC00115 Upregulated TNM stage (98)
Liu et al, 2018 LINC01296 Upregulated Clinical prognosis (100)
Lei et al, 2021 LINC00657 Downregulated Clinical prognosis, tumor size and TNM stage (101)
Hao et al, 2021 CASC7 Downregulated Survival rate, lymph node metastasis, and TNM stage. (104)
Wu et al, 2018 Liver cancer LINC00963 Upregulated Tumor size and TNM stage (119)
Zhong et al, 2022 AC099850.3 Upregulated Clinical prognosis (121)
Yue et al, 2022 LINC02154 Upregulated Overall survival (112)
Chen et al, 2018 NR027113 Upregulated Overall survival (113)
Zhou et al, 2022 NCK1-AS1 Upregulated TNM stage, BCLC stage and survival status (124)
Huang et al, 2018 PTTG3P Upregulated Tumor size, TNM stage and overall survival (116)
Gu et al, 2017 Pancreatic cancer MEG3 Upregulated Tumor size, Metastasis and Vascular invasion (135)
Luo et al, 2021 LINC01094 Upregulated Clinical prognosis (132)
Qiao et al, 2018 ABHD11-AS1 Upregulated Distant metastasis, TNM stage and tumor differentiation (133)
Zhang et al, 2018 SNHG1 Downregulated Tumor size and TNM stage (134)
Wang et al, 2018 Esophageal squamous cell carcinoma GAS5 Downregulated TNM stage (140)
Zhang et al, 2021 Gallbladder cancer CASC15 Downregulated TNM stage (147)
Cai et al, 2016 LINC00152 Upregulated Tumor status progression, lymph node invasion and TNM stage (148)

lncRNA, long non-coding RNA; LINC, long intergenic non-coding.